Bringing highly accurate diagnostics to the point of need

The scopeDx® platform uses proprietary type III CRISPR-Cas technology to detect nucleic acid sequences, dramatically enhancing the ability to detect genetic material with ease, speed and accuracy, for use in molecular diagnostics in infectious diseases, genotyping, and other applications

In work that emerged from the laboratory of Prof. Dr John van de Oost, well known for its role at the foreground of CRISPR-Cas research, scopeDx technology combines isothermal LAMP amplification with a novel type III CRISPR-Cas technology to detect target nucleic acid material. This brings together rapid isothermal amplification characteristics with extreme specificity due to the CRISPR-Cas module, and leads to a high performing diagnostic solution

https://www.nature.com/articles/s41467-021-25337-5

Since then, ScopeBio has improved and simplified the process. In one step, at one temperature, the amplification and read-out takes place in under 30 minutes.

Multiple samples (extraction and controls) are amplified and measured in real-time, for specific and fast confirmation of the presence of the pathogen of choice


Usable by anyone, anywhere

To make informed decisions at the location where you can make a difference, scopeDx® has been developed to facilitate this in several ways.

Simple extraction
The robust scopeDx® workflow includes a quick, hardware free, sample extraction step

One pot reaction
Minimal reagent handling steps improve the easy of use & reliability, and requires minimal training

Simple Hardware
The isothermal nature of scopeDx® allows for simple, intuitive, portable readout

Specific & Sensitive

We believe in the power of CRISPR-Cas to bring the accuracy of molecular testing to the point of need.

Molecular Detection
Suitable for the detection of both RNA and DNA, in under 25 minutes

Sensitive
Sensitive enough to detect the smallest amount of genetic material

Specific
Capable of detecting single nucleotide variations if desired

Contact us to learn more about how we can enable you to bring CRISPR-Cas diagnostics to your point of need